BACKGROUND To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124,miR-132,and brain-derived neurotrophic factor(BDNF)levels in patients with mild to moderate depression following coronary art...BACKGROUND To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124,miR-132,and brain-derived neurotrophic factor(BDNF)levels in patients with mild to moderate depression following coronary artery intervention[percuta-neous coronary intervention(PCI)]for coronary heart disease.Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305th Hospital of the People’s Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups:Experimental(treated with Shugan Jieyu capsules)and control(tr-eated with escitalopram oxalate tablets).This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression(HAMD-17)scores,metabolic equivalents,low-density lipoprotein cholesterol,BDNF,high-sensitivity C-reactive protein levels,miR-124 and miR-132 levels,distribution of immune-related lymphocyte subsets,and traditional Chinese me-dicine syndrome scores before and after 6 weeks of treatment.RESULTS No significant difference was observed in any index between the two groups before treatment(P>0.05).After treatment,the total efficacy rates were 93.33%and 90.00%in the experimental and control groups,respectively.Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group(P<0.05).No significant difference was observed in the metabolic equivalents between the two groups be-fore and after treatment(P>0.05).The levels of low-density lipoprotein cholesterol,high-sensitivity C-reactive pro-tein,and miR-132 were significantly lower,whereas those of miR-124,BDNF,CD3+T lymphocytes,CD3+CD4+T helper lymphocytes,and CD3+CD4+/CD3+CD8+cells were significantly higher in the experimental group com-pared to the control group(P<0.05).The incidence of adverse reactions during experimental group was signi-ficantly lower than that in control group(P<0.05).CONCLUSION Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI,and its me-chanism may contribute to the regulation of miR-124,miR-132,BDNF levels,and lymphoid immune cells.展开更多
基金the 305 Hospital Independent Scientific Research Fund,2024,No.24ZZJJLW-022.
文摘BACKGROUND To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124,miR-132,and brain-derived neurotrophic factor(BDNF)levels in patients with mild to moderate depression following coronary artery intervention[percuta-neous coronary intervention(PCI)]for coronary heart disease.Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305th Hospital of the People’s Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups:Experimental(treated with Shugan Jieyu capsules)and control(tr-eated with escitalopram oxalate tablets).This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression(HAMD-17)scores,metabolic equivalents,low-density lipoprotein cholesterol,BDNF,high-sensitivity C-reactive protein levels,miR-124 and miR-132 levels,distribution of immune-related lymphocyte subsets,and traditional Chinese me-dicine syndrome scores before and after 6 weeks of treatment.RESULTS No significant difference was observed in any index between the two groups before treatment(P>0.05).After treatment,the total efficacy rates were 93.33%and 90.00%in the experimental and control groups,respectively.Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group(P<0.05).No significant difference was observed in the metabolic equivalents between the two groups be-fore and after treatment(P>0.05).The levels of low-density lipoprotein cholesterol,high-sensitivity C-reactive pro-tein,and miR-132 were significantly lower,whereas those of miR-124,BDNF,CD3+T lymphocytes,CD3+CD4+T helper lymphocytes,and CD3+CD4+/CD3+CD8+cells were significantly higher in the experimental group com-pared to the control group(P<0.05).The incidence of adverse reactions during experimental group was signi-ficantly lower than that in control group(P<0.05).CONCLUSION Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI,and its me-chanism may contribute to the regulation of miR-124,miR-132,BDNF levels,and lymphoid immune cells.
文摘目的 探讨胃癌患者血清miR-216b和miR-132水平表达与临床预后的关系。方法 选取2018年1月~2020年2月在佳木斯市中心医院就诊的87例胃癌患者作为胃癌组,选择同期87例健康体检者作为对照组。实时荧光定量PCR (quantitative real-time PCR,qRT-PCR)检测血清中miR-216b和miR-132表达水平,分析胃癌患者血清miR-216b和miR-132表达水平与临床病理特征的关系。根据胃癌患者随访期间的生存或死亡情况,将胃癌患者分为预后良好组(生存,n=51)和预后不良组(死亡,n=36),用受试者工作特征(receiver operating characteristic,ROC)曲线分析血清miR-216b和miR-132表达水平对胃癌患者预后的预测价值;COX回归分析影响胃癌患者预后的因素。结果 与对照组比较,胃癌组血清中miR-216b (0.69±0.20 vs 1.02±0.24)和miR-132 (0.73±0.19 vs 1.01±0.22)表达水平降低,差异具有统计学意义(t=9.853,8.984,均P<0.001)。分化程度为低分化、TNM分期为Ⅲ±Ⅳ期、有淋巴结转移、有远处转移的胃癌患者血清miR-216b,miR-132表达水平低于分化程度为中、高分化、TNM分期为Ⅰ±Ⅱ期、无淋巴结转移、无远处转移的胃癌患者,差异具有统计学意义(t=6.266,3.412,2.890,2.723;4.999,3.734,4.180,5.502,均P<0.05)。与预后良好组比较,预后不良组胃癌患者血清中miR-216b(0.56±0.16vs 0.78±0.23)和miR-132(0.60±0.11 vs 0.82±0.25)表达水平降低,差异具有统计学意义(t=4.952,4.946,均P<0.001)。血清miR-216b,miR-132及二者联合预测胃癌患者预后的曲线下面积(area under the cure,AUC)分别为0.797 (95%CI:0.706~0.889),0.832(95%CI:0.745~0.918)和0.900 (95%CI:0.836~0.964);敏感度和特异度分别为83.3%,68.6%;97.2%,62.7%和79.4%,72.5%;当血清miR-216b,miR-132预测胃癌患者预后不良的截断值分别为0.66,0.76时,预测的敏感度较高。COX回归分析显示,miR-216b低表达、miR-132低表达、分化程度为低分化、TNM分期为Ⅲ+Ⅳ期、有淋巴结转移、有远处转移是胃癌患者预后不良的危险因素(均P<0.05)。结论miR-216b和miR-132在胃癌患者血清中呈低表达,二者可作为预测胃癌患者预后的有效生物标志物。
